-
Posted by
Two Blokes Jun 30 -
Filed in
Stock
-
3 views
VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today shared a summary of its H1 2025 accomplishments and provided an outline of its strategic objectives for H2 2025 - against the backdrop of a rapidly evolving global AI landscape.
